Cytori Therapeutics Announces Company Presentation the 2012 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum on October 30

Cytori Therapeutics Announces Company Presentation the 2012 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum on October 30

<0> Cytori Therapeutics, Inc.Megan McCormick, +1-858-875-5279 </0>

(NASDAQ: CYTX) will give a company presentation at the Investor and Partnering Forum on Tuesday, October 30.

The following are specific details regarding Cytori’s presentation at the conference:

The presentation will be recorded and will be available on the Webcasts page of the Cytori’s the week following the conference.

The Investor and Partnering Forum is being organized by the Alliance for Regenerative Medicine (ARM) and the California Institute for Regenerative Medicine to profile the industry’s most exciting technologies.

Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® system product family.

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.